BR9508254A - Componente de rna de telomerase de mamífero oligonucleotídeo na forma substancialmente pura plasmídeo de expressão recombinante célula hospedeira eucariótica processo para produzir uma enzima telomerase recombinante composição processos para identificar polinucleotídeos de componente de rna de telomerase de mamífero mutantes para identificar agentes candidatos de modulação de telomerase e para inibir a atividade de telomerase em células de humanos polinucleotídeo para terapia genética de uma doença de humano ribossomo e processos para detectara presença de uma condição relacianada á telomerase em um paciente para detectar a presença de uma condição neoplástica em um paciente e para determinar a presença de componente de rna de telomerase - Google Patents

Componente de rna de telomerase de mamífero oligonucleotídeo na forma substancialmente pura plasmídeo de expressão recombinante célula hospedeira eucariótica processo para produzir uma enzima telomerase recombinante composição processos para identificar polinucleotídeos de componente de rna de telomerase de mamífero mutantes para identificar agentes candidatos de modulação de telomerase e para inibir a atividade de telomerase em células de humanos polinucleotídeo para terapia genética de uma doença de humano ribossomo e processos para detectara presença de uma condição relacianada á telomerase em um paciente para detectar a presença de uma condição neoplástica em um paciente e para determinar a presença de componente de rna de telomerase

Info

Publication number
BR9508254A
BR9508254A BR9508254A BR9508254A BR9508254A BR 9508254 A BR9508254 A BR 9508254A BR 9508254 A BR9508254 A BR 9508254A BR 9508254 A BR9508254 A BR 9508254A BR 9508254 A BR9508254 A BR 9508254A
Authority
BR
Brazil
Prior art keywords
telomerase
patient
processes
component
mammalian
Prior art date
Application number
BR9508254A
Other languages
English (en)
Inventor
Bryant Villeponteau
Junli Feng
Walter Funk
William H Andrews
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/330,123 external-priority patent/US5583016A/en
Priority claimed from US08/472,802 external-priority patent/US5958680A/en
Priority claimed from US08/482,115 external-priority patent/US5776679A/en
Application filed by Geron Corp filed Critical Geron Corp
Publication of BR9508254A publication Critical patent/BR9508254A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C59/00—Surface shaping of articles, e.g. embossing; Apparatus therefor
    • B29C59/02—Surface shaping of articles, e.g. embossing; Apparatus therefor by mechanical means, e.g. pressing
    • B29C59/04—Surface shaping of articles, e.g. embossing; Apparatus therefor by mechanical means, e.g. pressing using rollers or endless belts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/15—Nucleic acids forming more than 2 strands, e.g. TFOs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Mechanical Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Shaping Of Tube Ends By Bending Or Straightening (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
BR9508254A 1994-07-07 1995-07-06 Componente de rna de telomerase de mamífero oligonucleotídeo na forma substancialmente pura plasmídeo de expressão recombinante célula hospedeira eucariótica processo para produzir uma enzima telomerase recombinante composição processos para identificar polinucleotídeos de componente de rna de telomerase de mamífero mutantes para identificar agentes candidatos de modulação de telomerase e para inibir a atividade de telomerase em células de humanos polinucleotídeo para terapia genética de uma doença de humano ribossomo e processos para detectara presença de uma condição relacianada á telomerase em um paciente para detectar a presença de uma condição neoplástica em um paciente e para determinar a presença de componente de rna de telomerase BR9508254A (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27210294A 1994-07-07 1994-07-07
US08/330,123 US5583016A (en) 1994-07-07 1994-10-27 Mammalian telomerase
US08/472,802 US5958680A (en) 1994-07-07 1995-06-07 Mammalian telomerase
US08/482,115 US5776679A (en) 1994-07-07 1995-06-07 Assays for the DNA component of human telomerase
PCT/US1995/008530 WO1996001835A1 (en) 1994-07-07 1995-07-06 Mammalian telomerase

Publications (1)

Publication Number Publication Date
BR9508254A true BR9508254A (pt) 1997-12-23

Family

ID=27501040

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9508254A BR9508254A (pt) 1994-07-07 1995-07-06 Componente de rna de telomerase de mamífero oligonucleotídeo na forma substancialmente pura plasmídeo de expressão recombinante célula hospedeira eucariótica processo para produzir uma enzima telomerase recombinante composição processos para identificar polinucleotídeos de componente de rna de telomerase de mamífero mutantes para identificar agentes candidatos de modulação de telomerase e para inibir a atividade de telomerase em células de humanos polinucleotídeo para terapia genética de uma doença de humano ribossomo e processos para detectara presença de uma condição relacianada á telomerase em um paciente para detectar a presença de uma condição neoplástica em um paciente e para determinar a presença de componente de rna de telomerase

Country Status (23)

Country Link
EP (2) EP1293565A3 (pt)
JP (2) JPH10505488A (pt)
KR (1) KR100789741B1 (pt)
CN (1) CN1231491C (pt)
AT (1) ATE308554T1 (pt)
AU (1) AU696702B2 (pt)
BG (1) BG63573B1 (pt)
BR (1) BR9508254A (pt)
CA (1) CA2194393C (pt)
CZ (1) CZ3497A3 (pt)
DE (1) DE69534568T2 (pt)
DK (1) DK0778842T3 (pt)
ES (1) ES2251720T3 (pt)
FI (1) FI970026A (pt)
HK (1) HK1011691A1 (pt)
HU (1) HUT78054A (pt)
IS (1) IS4408A (pt)
NO (1) NO970041L (pt)
NZ (1) NZ289720A (pt)
PL (1) PL181019B1 (pt)
RO (1) RO117328B1 (pt)
UA (1) UA47407C2 (pt)
WO (1) WO1996001835A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067497B2 (en) 1992-09-29 2006-06-27 Isis Pharmaceuticals, Inc. Modulation of telomere length by oligonucleotides having a G-core sequence
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5972605A (en) * 1994-07-07 1999-10-26 Geron Corporation Assays for regulators of mammalian telomerase expression
US6545133B1 (en) 1995-08-04 2003-04-08 Geron Corporation Methods for purifying telomerase
US6517834B1 (en) 1995-08-04 2003-02-11 Geron Corporation Purified telomerase
US5968506A (en) * 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US5858777A (en) 1995-09-08 1999-01-12 Geron Corporation Methods and reagents for regulating telomere length and telomerase activity
JP2000512126A (ja) * 1995-11-16 2000-09-19 ダーム、ミヒャエル・ヴェー 体液中の腫瘍細胞を数量化するための方法およびかかる方法に適合した試験キット
AU2593697A (en) * 1996-03-28 1997-10-17 Albert Einstein College Of Medicine Of Yeshiva University Transgenic organisms with altered telomerase activity
US6015710A (en) * 1996-04-09 2000-01-18 The University Of Texas System Modulation of mammalian telomerase by peptide nucleic acids
JPH1052300A (ja) * 1996-06-03 1998-02-24 Kyowa Hakko Kogyo Co Ltd 細胞内テロメラーゼ活性の測定法
JPH1028600A (ja) * 1996-07-17 1998-02-03 Kyowa Hakko Kogyo Co Ltd テロメラーゼ活性の測定法
ATE552341T1 (de) 1996-10-01 2012-04-15 Geron Corp Katalytische untereinheit der menschlichen telomerase
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6093809A (en) 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US5846723A (en) * 1996-12-20 1998-12-08 Geron Corporation Methods for detecting the RNA component of telomerase
WO1998028442A1 (en) * 1996-12-20 1998-07-02 Geron Corporation Methods for detecting and inhibiting the rna component of telomerase
WO1998037181A2 (en) * 1997-02-20 1998-08-27 Whitehead Institute For Biomedical Research Telomerase catalytic subunit gene and encoded protein
ATE250130T1 (de) * 1997-04-04 2003-10-15 Geron Corp Gereinigte telomerase
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
AU745420B2 (en) * 1997-06-20 2002-03-21 Bayer Aktiengesellschaft Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
EP1571215A3 (en) * 1997-07-01 2007-10-31 Cambia Biosystems LLC Vertebrate telomerase genes and proteins and uses thereof
EP0917579A1 (en) * 1997-07-01 1999-05-26 Cambia Biosystems LLC Vertebrate telomerase genes and proteins and uses thereof
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
DE19757300A1 (de) * 1997-12-22 1999-06-24 Roche Diagnostics Gmbh Nachweis von Harnblasenkarzinom in einer Urinprobe
GB9801902D0 (en) * 1998-01-29 1998-03-25 Cancer Res Campaign Tech A gene promoter
DE19804372A1 (de) 1998-02-04 1999-08-05 Michael W Dr Dr Dahm Verfahren zur quantitativen Bestimmung von Tumorzellen in einer Körperflüssigkeit und dazu geeignete Testkits
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6358739B1 (en) * 1999-04-12 2002-03-19 Modex Therapeutiques, S.A. Transiently immortalized cells
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
WO2000074667A2 (en) * 1999-06-04 2000-12-14 Au Jessie L S Compositions active in telomere damage comprising a taxane and telomerase inhibitor
DK1210357T3 (da) 1999-09-10 2008-07-21 Geron Corp Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf
WO2001036971A1 (fr) * 1999-11-16 2001-05-25 Kyowa Hakko Kogyo Co., Ltd. Methode de recherche de substance d'inhibition de liaison entre des sous-unites de telomerase
PL1644009T3 (pl) * 2003-06-23 2018-07-31 Telomerase Activation Sciences, Inc. Kompozycje do zwiększania aktywności telomerazy i leczenia zakażenia hiv
DK3342425T3 (da) 2003-09-09 2020-03-16 Geron Corp Modificerede oligonukleotider til inhibering af telomerase
JP4635196B2 (ja) * 2005-03-04 2011-02-16 国立大学法人広島大学 遺伝子導入細胞、及びそれを用いたテロメラーゼ誘導物質の検出方法
WO2008094640A2 (en) 2007-01-30 2008-08-07 Geron Corporation Compounds having anti-adhesive effects on cancer cells
US9447467B2 (en) 2009-04-21 2016-09-20 Genetic Technologies Limited Methods for obtaining fetal genetic material
JP6021018B2 (ja) * 2011-05-30 2016-11-02 国立大学法人豊橋技術科学大学 改良されたオリゴヌクレオチドおよびそのオリゴヌクレオチドを含む医薬組成物
US20150125438A1 (en) * 2012-07-20 2015-05-07 Sang Jae Kim Anti-Inflammatory Peptides and Composition Comprising the Same
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
SG11201601890UA (en) * 2013-09-13 2016-04-28 Hoffmann La Roche Application of oligo-dt molecules to avoid generation of high molecular pcr products induced by polya-carrier
JOP20200257A1 (ar) 2014-05-01 2017-06-16 Geron Corp تركيبات أوليجو نوكليوتيد وطرق لتحضيرها
KR101628890B1 (ko) * 2015-09-03 2016-06-09 주식회사 학표벽지 엠보싱 벽지 제조 장치

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4312686A (en) * 1980-02-11 1982-01-26 American Biltrite Inc. Printed and embossed floor covering and method and apparatus for its manufacture
JPH02179729A (ja) * 1988-12-30 1990-07-12 Shinetsu Kogyo Kk ゲートル巻きするラッピングフィルムの製造法
US5489508A (en) * 1992-05-13 1996-02-06 University Of Texas System Board Of Regents Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
WO1995013382A1 (en) * 1993-11-12 1995-05-18 Geron Corporation Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
EP0666313A3 (en) * 1994-01-27 1996-03-06 Univ Iowa State Res Found Inc Targeting telomerase in gene therapy for cancer.
US5876979A (en) * 1994-07-07 1999-03-02 Cold Spring Harbor Laboratory RNA component of mouse, rat, Chinese hamster and bovine telomerase
JPH08294966A (ja) * 1995-04-26 1996-11-12 Nippon Shokubai Co Ltd 樹脂成形品の連続成形方法
JPH10119130A (ja) 1996-10-22 1998-05-12 Japan Steel Works Ltd:The 連続発泡体の製造方法及び装置
KR100815605B1 (ko) * 2002-02-18 2008-03-20 바프렉스 주식회사 공압출 다층필름의 제조방법 및 장치

Also Published As

Publication number Publication date
KR100789741B1 (ko) 2008-01-02
DE69534568T2 (de) 2006-07-27
NO970041L (no) 1997-03-06
RO117328B1 (ro) 2002-01-30
IS4408A (is) 1997-01-03
JP2002272489A (ja) 2002-09-24
DK0778842T3 (da) 2006-03-20
EP0778842A4 (en) 1999-08-11
HUT78054A (hu) 1999-07-28
EP1293565A2 (en) 2003-03-19
KR20050058527A (ko) 2005-06-17
PL181019B1 (pl) 2001-05-31
ATE308554T1 (de) 2005-11-15
CZ3497A3 (en) 1997-10-15
EP1293565A3 (en) 2004-05-12
CN1158617A (zh) 1997-09-03
WO1996001835A1 (en) 1996-01-25
BG101103A (en) 1997-10-31
FI970026A (fi) 1997-03-03
NZ289720A (en) 1999-03-29
JP4068861B2 (ja) 2008-03-26
HK1011691A1 (en) 1999-07-16
CN1231491C (zh) 2005-12-14
AU2964795A (en) 1996-02-09
JPH10505488A (ja) 1998-06-02
NO970041D0 (no) 1997-01-06
AU696702B2 (en) 1998-09-17
FI970026A0 (fi) 1997-01-03
CA2194393A1 (en) 1996-01-25
EP0778842B1 (en) 2005-11-02
DE69534568D1 (de) 2005-12-08
BG63573B1 (bg) 2002-05-31
UA47407C2 (uk) 2002-07-15
PL318169A1 (en) 1997-05-26
EP0778842A1 (en) 1997-06-18
ES2251720T3 (es) 2006-05-01
CA2194393C (en) 2002-06-25

Similar Documents

Publication Publication Date Title
BR9508254A (pt) Componente de rna de telomerase de mamífero oligonucleotídeo na forma substancialmente pura plasmídeo de expressão recombinante célula hospedeira eucariótica processo para produzir uma enzima telomerase recombinante composição processos para identificar polinucleotídeos de componente de rna de telomerase de mamífero mutantes para identificar agentes candidatos de modulação de telomerase e para inibir a atividade de telomerase em células de humanos polinucleotídeo para terapia genética de uma doença de humano ribossomo e processos para detectara presença de uma condição relacianada á telomerase em um paciente para detectar a presença de uma condição neoplástica em um paciente e para determinar a presença de componente de rna de telomerase
Svoboda et al. Effect of sequence, adduct type, and opposing lesions on the binding and repair of ultraviolet photodamage by DNA photolyase and (A) BC excinuclease
DE69433626D1 (de) N-2 substituierte purine
DE50015772D1 (de) Sequenz-spezifische DNA-Rekombination in eukaryotischen Zellen
BR9814816A (pt) Novas moléculas repórter fluorescentes e suas aplicações incluindo análises de caspases
EP1795203A3 (en) Fhit proteins and nucleic acids and methods based thereon
ATE323169T1 (de) Plasmid zur verabreichung von nukleine säuren und verwendungsverfahren
WO2001030965A3 (en) Methods of in vivo gene transfer using a sleeping beauty transposon system
BR0014115A (pt) Métodos de produzir um panto-composto, pantotenato e beta-alanina, de aumentar a produção de um panto-composto e de edentificar compostos que modulam a atividade da pantotenato cinase, microorganismo recombinante, vetor, molécula de ácido nuleico isolada, polipetìdeo e proteìna da pantotenato cinase isolada
Ching et al. A selenium-containing nucleoside at the first position of the anticodon in seleno-tRNAGlu from Clostridium sticklandii.
Razin et al. Nuclear matrix attachment regions and topoisomerase II binding and reaction sites in the vicinity of a chicken DNA replication origin
AU690858B2 (en) Oligonucleotide modulation of cell adhesion
Sahagan et al. A small, unstable RNA molecule of Escherichia coli: spot 42 RNA: I. Nucleotide sequence analysis
Griffin Studies and sequences of Escherichia coli 4.5 S RNA.
NZ289607A (en) Isolated polynucleotide encoding serum paraoxonase; transformed host cell; production of polypeptide serum paraoxonase
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
WO2003031572A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
Schimmel Approaches to understanding the mechanism of specific protein-transfer RNA interactions
BR1100617A (pt) Oligonucleotìdeo tendo seq id no: 22, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula, oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27, processo para inibir a sìntese de moléculas de adesão intercelulare em uma célula compreendendo contactar a célula in vitro com um oligonucleotìdeo tendo seq id no: 1, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 17, 20, 21, 23, 24, 25, 26 ou 27
WO2004005475A3 (en) Purified and isolated heparan sulfate 3-o-sulfotransferase isoform 5 nucleic acids and polypeptides and therapeutic and screening methods using same
Hovanessian et al. Protein kinase in human plasma analogous to that present in control and interferon-treated HeLa cells
WO2003076578A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
Lebedeva et al. Photoaffinity labeling of proteins in bovine testis nuclear extract
WO2000029589A8 (en) Methioninase gene therapy for tumor treatment
DE69833104D1 (de) Glaukom diagnose und behandlung

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]

Free format text: SUSPENSAO DO ANDAMENTO DO PEDIDO PARA QUE SEJA COMPLEMENTADA A RETRIBUICAO EQUIVALENTE AO PEDIDO DEEXAME DE 15 (QUINZE) REIVINDICACOES VISTO QUE A RETRIBUICAO APRESENTADA REFERE-SE A 12 (DOZE) REIVIDICACOES.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 27/09/2005, OBSERVADAS AS CONDICOES LEGAIS.

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 27/09/2015